Cite
HARVARD Citation
Uttervall, K. et al. (2019). Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European journal of haematology. pp. 247-254. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Uttervall, K. et al. (2019). Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma. European journal of haematology. pp. 247-254. [Online].